Crescent Biopharma announces clinical updates.
- Enrolled patients in CR-001 combination trials with chemo in ASCEND.
- Initiated ADC combination studies with CR-001.
- Planned Phase 1/2 APOLLO trial for CR-002 in Q4 2026.
CBIO
CRESCENT BIOPHARMA, INC. SEC filings
Every EDGAR filing for CRESCENT BIOPHARMA, INC. (CBIO), newest first, with AI summaries and stories.
- Ticker
- CBIO
- CIK
- 1253689
- Sector
- Biotech and pharma
- Latest filing
- 3d
Next: earnings expected ~Nov 2 · 10-Q expected ~Nov 9 (deadline Nov 16)
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
ROUTINE8-KCRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINE4CRESCENT BIOPHARMA, INC.CBIOLIVE 7 insider filings
Ellie Eunkyung Im, insider filing for CBIO
Show all 7
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
Ellie Eunkyung Im, reporting
ROUTINES-8CRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINE144CRESCENT BIOPHARMA, INC.CBIOLIVE 2 Form 144 notices
Joshua T Brumm, planned sale of CBIO shares
Show all 2
- 144Planned insider sale of CBIO shares
- 144Planned insider sale of CBIO shares
Joshua T Brumm, reporting
ROUTINE144CRESCENT BIOPHARMA, INC.CBIOLIVE 2 Form 144 notices
Jonathan McNeill, planned sale of CBIO shares
Show all 2
- 144Planned insider sale of CBIO shares
- 144Planned insider sale of CBIO shares
Jonathan McNeill, reporting
ROUTINESCHEDULE 13G/ACRESCENT BIOPHARMA, INC.CBIOLIVE Ownership stake disclosure by BALYASNY ASSET MANAGEMENT L.P. (amended)
BALYASNY ASSET MANAGEMENT L.P., filed by
ROUTINEEFFECTCRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINEPOS AMCRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINE424B3CRESCENT BIOPHARMA, INC.CBIOLIVE NOTABLE10-QCRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINE8-KCRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINE4CRESCENT BIOPHARMA, INC.CBIOLIVE Peter Evan Harwin, insider filing for CBIO
Peter Evan Harwin, reporting · Fairmount Healthcare Fund II L.P., reporting · +2 more
NOTABLESCHEDULE 13D/ACRESCENT BIOPHARMA, INC.CBIOLIVE Ownership stake disclosure by Fairmount Funds Management LLC (amended)
Fairmount Funds Management LLC, filed by
ROUTINE8-KCRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINE424B5CRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINE8-KCRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINE424B5CRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINEEFFECTCRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINES-3CRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINE4CRESCENT BIOPHARMA, INC.CBIOLIVE 7 insider filings
Ryan Lynch, insider filing for CBIO
Show all 7
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
Ryan Lynch, reporting
ROUTINE424B3CRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINE10-Q/ACRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINE4CRESCENT BIOPHARMA, INC.CBIOLIVE 5 insider filings
Jonathan Violin, insider filing for CBIO
Show all 5
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
- 4Insider filing for CBIO
Jonathan Violin, reporting
ROUTINE8-KCRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINESCHEDULE 13G/ACRESCENT BIOPHARMA, INC.CBIOLIVE Ownership stake disclosure by TANG CAPITAL MANAGEMENT LLC (amended)
TANG CAPITAL MANAGEMENT LLC, filed by
ROUTINESCHEDULE 13GCRESCENT BIOPHARMA, INC.CBIOLIVE Ownership stake disclosure by BALYASNY ASSET MANAGEMENT L.P.
BALYASNY ASSET MANAGEMENT L.P., filed by
ROUTINE424B3CRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINE8-KCRESCENT BIOPHARMA, INC.CBIOLIVE NOTABLE10-QCRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINEDEFA14ACRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINEDEFA14ACRESCENT BIOPHARMA, INC.CBIOLIVE ROUTINEDEF 14ACRESCENT BIOPHARMA, INC.CBIOLIVE